Introduction: Mortality from acute myocardial infarction (AMI) remains substantial. The current study is aimed at developing a novel simple risk score for AMI. Methods: The Coronary Artery Tree description and Lesion EvaluaTion (CatLet) extended validation trial (ChiCTR2000033730) and the CatLet validation trial (ChiCTR-POC-17013536), both being registered with <ext-link ext-link-type="uri" xlink:href="http://chictr.org" xmlns:xlink="http://www.w3.org/1999/xlink">chictr.org</ext-link>, served as the derivation and validation datasets, respectively. Both datasets included 1,018 and 308 patients, respectively. They all suffered from AMI and underwent percutaneous intervention (PCI). The endpoint was 4-year all-cause death. Lasso regression analysis was used for covariate selection and coefficient estimation. Results: Of 26 candidate predictor variables, the four strongest predictors for 4-year mortality were included in this novel risk score with an acronym of BACEF (serum alBumin, Age, serum Creatinine, and LVEF). This score was well calibrated and yielded an AUC (95% CI) statistics of 0.84 (0.80–0.87) in internal validation, 0.89 (0.83–0.95) in internal-external (temporal) validation, and 0.83 (0.77–0.89) in external validation. Notably, it outperformed the ACEF, ACEF II, GRACE scores with respect to 4-year mortality prediction. Conclusion: A simple risk score for 4-year mortality risk stratification was developed, extensively validated, and calibrated in patients with AMI. This novel BACEF score may be a useful risk stratification tool for patients with AMI.

1.
Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The timi risk score for unstable angina/non-st elevation mi: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835–42.
2.
Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the heart score. Neth Heart J. 2008;16(6):191–6.
3.
Fox KA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated grace risk score. BMJ Open. 2014;4(2):e004425.
4.
Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345–53.
5.
Mrdovic I, Savic L, Krljanac G, Asanin M, Perunicic J, Lasica R, et al. Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The risk-pci score. Int J Cardiol. 2013;162(3):220–7.
6.
Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 esc guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation. Eur Heart J. 2021;42(14):1289–367.
7.
Wang H, He Y, Fan JL, Li X, Zhou BY, Jiang TB, et al. The predictive value of CatLet© angiographic scoring system for long-term prognosis in patients with acute myocardial infarction presenting [{GT}]12 h after symptom onset. Front Cardiovasc Med. 2022;9:943229.
8.
Xu MX, Ruddy TD, Schoenhagen P, Bartel T, Di Bartolomeo R, von Kodolitsch Y, et al. The catlet score and outcome prediction in acute myocardial infarction for patients undergoing primary percutaneous intervention: a proof-of-concept study. Catheter Cardiovasc Interv. 2020;96(3):E220–E229.
9.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third Universal Definition of Myocardial Infarction. Circulation. 2012;126(16):2020–35.
10.
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51.
11.
Ahrens A, Hansen CB, Schaffer ME. Lassopack: model selection and prediction with regularized regression in stata. STATA J. 2020;20(1):176–235.
12.
Riley RD, Ensor J, Snell KIE, Harrell FEJr., Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441.
13.
Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (tripod): the tripod statement. Bmj. 2015;350:g7594.
14.
Ranucci M, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G. Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. Circulation. 2009;119(24):3053–61.
15.
Ranucci M, Pistuddi V, Scolletta S, de Vincentiis C, Menicanti L. The acef ii risk score for cardiac surgery: updated but still parsimonious. Eur Heart J. 2018;39(23):2183–9.
16.
Leening MJ, Vedder MM, Witteman JC, Pencina MJ, Steyerberg EW. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. Ann Intern Med. 2014;160(2):122–31.
17.
Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, et al. Risk factors and outcome in european cardiac surgery: analysis of the euroscore multinational database of 19030 patients. Eur J Cardio Thorac Surg. 1999;15(6):816–22; discussion 822-813.
18.
Wykrzykowska JJ, Garg S, Onuma Y, de Vries T, Goedhart D, Morel MA, et al. Value of age, creatinine, and ejection fraction (acef score) in assessing risk in patients undergoing percutaneous coronary interventions in the 'all-comers' leaders trial. Circ Cardiovasc Interv. 2011;4(1):47–56.
19.
Pyxaras SA, Mangiacapra F, Wijns W, Di Serafino L, De Vroey F, Toth G, et al. Acef and clinical syntax score in the risk stratification of patients with heavily calcified coronary stenosis undergoing rotational atherectomy with stent implantation. Catheter Cardiovasc Interv. 2014;83(7):1067–73.
20.
Xia M, Zhang C, Gu J, Chen J, Wang LC, Lu Y, et al. Impact of serum albumin levels on long-term all-cause, cardiovascular, and cardiac mortality in patients with first-onset acute myocardial infarction. Clin Chim Acta. 2018;477:89–93.
21.
Yang Q, He YM, Cai DP, Yang XJ, Xu HF. Risk burdens of modifiable risk factors incorporating lipoprotein (a) and low serum albumin concentrations for first incident acute myocardial infarction. Sci Rep. 2016;6:35463.
22.
He YM, Yang Q, Yang XJ, Zhao X, Xu HF, Qian YX. Serum albumin concentrations, effect modifiers and first incident acute myocardial infarction: a cross-sectional study of 1552 cases and 6680 controls. Clin Chim Acta. 2016;454:49–56.
23.
He YM, Yang XJ, Hui J, Jiang TB, Song JP, Liu ZH, et al. Low serum albumin levels in patients with paroxysmal atrial fibrillation: what does it mean?Acta Cardiol. 2006;61(3):333–7.
24.
Ronit A, Kirkegaard-Klitbo DM, Dohlmann TL, Lundgren J, Sabin CA, Phillips AN, et al. Plasma albumin and incident cardiovascular disease: results from the cgps and an updated meta-analysis. Arterioscler Thromb Vasc Biol. 2020;40(2):473–82.
25.
Zhu L, Chen M, Lin X. Serum albumin level for prediction of all-cause mortality in acute coronary syndrome patients: a meta-analysis. Biosci Rep. 2020;40(1):40.
26.
Arques S. Serum albumin and cardiovascular disease: state-of-the-art review. Ann Cardiol Angeiol. 2020;69(4):192–200.
27.
Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW; Topic Group ‘Evaluating diagnostic tests and prediction models’ of the STRATOS initiative. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17(1):230.
28.
Ge Z-Y, He Y, Jiang T-B, Tao J-Y, He Y-M. Value of serum albumin, age, serum creatinine, and left ventricular ejection fraction for the assessment of 4-year mortality risk in patients with acute myocardial infarction: parsimonious and better performed. medRxiv. 2022:2022.
You do not currently have access to this content.